- Reaction score
- 732
Hairclone CEO Paul Kemp has recently said to FT that: "We are continuing to work closely with the Cell Therapy facility in Newcastle to transfer our manufacturing process to GMP and are still on track to be able to offer a cell expansion service to clinicians for use in the UK in 2021 though as I have stressed we can’t market this as a treatment nor claim any efficacy. It is entirely a decision between patient and clinician whether they feel this would address a "Special Clinical Need.”
On their FAQ site they have written: "We hope that around the end of 2020 (now adjusted to 2021) HairClone will be able to offer a “Cell Expansion Service” to clinical partners for use in the UK."
Thoughts? Does anyone know what this "Cell expansion service" mean? I haven't found any info on this at all.
On their FAQ site they have written: "We hope that around the end of 2020 (now adjusted to 2021) HairClone will be able to offer a “Cell Expansion Service” to clinical partners for use in the UK."
Thoughts? Does anyone know what this "Cell expansion service" mean? I haven't found any info on this at all.